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Background-—Guidelines for hypertension vary in their preference for initial combination therapy or initial monotherapy, stratiﬁed
by patient proﬁle; therefore, we compared the efﬁcacy and tolerability of these approaches.
Methods and Results-—We performed a 1-year, double-blind, randomized controlled trial in 605 untreated patients aged 18 to 79
years with systolic blood pressure (BP) ≥150 mm Hg or diastolic BP ≥95 mm Hg. In phase 1 (weeks 0–16), patients were
randomly assigned to initial monotherapy (losartan 50–100 mg or hydrochlorothiazide 12.5–25 mg crossing over at 8 weeks), or
initial combination (losartan 50–100 mg plus hydrochlorothiazide 12.5–25 mg). In phase 2 (weeks 17–32), all patients received
losartan 100 mg and hydrochlorothiazide 12.5 to 25 mg. In phase 3 (weeks 33–52), amlodipine with or without doxazosin could be
added to achieve target BP. Hierarchical primary outcomes were the difference from baseline in home systolic BP, averaged over
phases 1 and 2 and, if signiﬁcant, at 32 weeks. Secondary outcomes included adverse events, and difference in home systolic BP
responses between tertiles of plasma renin. Home systolic BP after initial monotherapy fell 4.9 mm Hg (range: 3.7–6.0 mm Hg)
less over 32 weeks (P<0.001) than after initial combination but caught up at 32 weeks (difference 1.2 mm Hg [range: 0.4 to
2.8 mm Hg], P=0.13). In phase 1, home systolic BP response to each monotherapy differed substantially between renin tertiles,
whereas response to combination therapy was uniform and at least 5 mm Hg more than to monotherapy. There were no
differences in withdrawals due to adverse events.
Conclusions-—Initial combination therapy can be recommended for patients with BP >150/95 mm Hg.
Clinical Trial Registration-—URL: http://www.ClinicalTrials.gov. Unique identiﬁer: NCT00994617. ( J Am Heart Assoc. 2017;6:
e006986. DOI: 10.1161/JAHA.117.006986.)
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M ost hypertensive patients do not have their bloodpressure (BP) controlled by monotherapy. Yet combi-
nations of drugs are not commonly used as initial therapy for
hypertension despite studies that suggest the advantages of
this approach.1–3 Initial treatment of hypertension with
combination therapy has been discouraged because of
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concern about excessive reduction in BP, increased side
effects, and the difﬁculty of attributing adverse events to 1
drug. However, the alternatives also have risks and down-
sides. The most common practice, long recommended by
guidelines, is to start with 1 drug and add another. But this
could result in patients continuing to take a drug that is
ineffective. Some guidelines recommend tailoring initial
therapy to patient characteristics such as age and ethnicity,
which may be surrogates for plasma renin status.4,5 An
alternative is sequential monotherapy to ﬁnd each patient’s
best monotherapy, but this takes time and endurance, during
which uncontrolled hypertension is not without risk.6
Evidence that the prompt versus delayed control of BP was
of beneﬁt came initially from the VALUE (Valsartan Antihy-
pertensive Long-term Use Evaluation) trial. In that study, a BP
difference of 3.8 mm Hg in the ﬁrst 3 months of the trial
was associated with fewer cardiovascular events, particularly
stroke and mortality.7 Recent observational analyses have
conﬁrmed that delays in achieving BP control are not benign
and that rapid BP control is important.8,9
These observations have led to recommendations in some
guidelines to consider initial combination therapy in patients
with BP >160/100 mm Hg, but this practice has not been
widely adopted. We thought practitioners might be persuaded
by a ﬁnding that superior BP control by initial combination
was sustained—indeed, this possibility was suggested by the
results of the VALUE7 and ASCOT (Anglo Scandinavian
Cardiac Outcomes Trial)10 studies. In these studies, the BP
lowering in participants randomized to the less effective of 2
treatments early in the study “never caught up” with that
achieved by the other group, despite the former eventually
receiving more drug therapy. Furthermore, our previous study
of dual therapy versus monotherapy suggested that partici-
pants who began initial dual therapy always appeared to have
better BP control than the monotherapy group, perhaps
because combination therapy attenuated compensatory
changes induced by monotherapy.11
The objective of PATHWAY-1 (Prevention And Treatment of
Hypertension With Algorithm-based Therapy - study 1) was to
test the superiority of home systolic BP (HSBP) control of initial
combination therapy compared with the more conventional
practice of initial monotherapy. Half of the patients received
combination from the start, and all participants received
combination therapy after the ﬁrst 4 months; this design
allowed us to rigorously test the “never-catch-up” hypothesis. If
this were true, we would ﬁnd a difference in BP at 8 months
despite both groups receiving the same therapy during the
previous 4 months.We powered the study to detect a 4-mm Hg
difference in HSBP, as we deemed this difference would be
clinically important. An important secondary objective of this
design was to test the predictors (age, renin12) of response to
treatment, which predicts the response to monotherapy but
not, we hypothesized, to combination therapy. Although we
evidently expected the average BP response to combination
therapy to be superior to the average response tomonotherapy,
the crossover design of phase 1 enabled us to address the
question of whether personalized monotherapy achieves a BP
response that is not only superior to average but also
comparable to the effect of combination.
Methods
Setting
The British Hypertension Society Research Network of
academic investigators recruited participants from both
primary and secondary care.
Study Design
Patients who were aged 18 to 79 years with a diagnosis of
essential hypertension, who had systolic BP >150 mm Hg or
diastolic BP >95 mm Hg, and who were either never treated
or who had received 1 drug class in the previous year were
eligible for inclusion in PATHWAY-1. This was a parallel-group,
randomized, double-blind, phase 4 trial conducted in 11
secondary and 2 primary care centers in the United Kingdom.
A full list of inclusion and exclusion criteria is provided in
Table S1.
Participants were enrolled between February 2010 to
November 2013; the study ended (last patient completed the
Clinical Perspective
What Is New?
• Initial combination therapy for hypertension achieved target
blood pressure in twice as many participants as initial
monotherapy, without any difference in withdrawals due to
adverse events.
• The blood pressure reduction by losartan and
hydrochlorothiazide was greatest in the top and bottom
tertiles, respectively, of plasma renin.
• The more effective monotherapy, identiﬁed by renin proﬁling
or sequential comparison of the 2 drugs, reduced systolic
blood pressure, on average, by 5 mm Hg less than initial
combination therapy.
What Are the Clinical Implications?
• Initial combination therapy can be recommended for the
treatment of blood pressure levels >150/95 mm Hg.
• Initial combination therapy obviates the routine measure-
ment of plasma renin, but extreme values can help the
selection of monotherapy when desired.
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study) in December 2014. The study design and rationale
have been published.13 A study schematic is shown in
Figure 1 (a more detailed diagram is shown in Figure S1).
After a 4-week, single-blind, placebo run-in during which
any previous antihypertensive monotherapy was withdrawn,
there were 3 sequential phases of active treatment during
which investigators and participants were blinded to the initial
random assignment. In the ﬁrst phase, weeks 0–16, half of
the participants started monotherapy with either losartan or
HCTZ (hydrochlorothiazide), and half started a combination of
losartan plus HCTZ. In the second phase (weeks 16–32), all
participants received the same combination of losartan plus
HCTZ. In the third phase, patients received additional open-
label medication with amlodipine and/or doxazosin, depen-
dent on whether their BP was controlled and whether they
tolerated the amlodipine. The primary end points were
measured at the end of the second phase; the third phase
allowed extended assessment of the sustained effect of the
difference in randomly assigned drugs in the ﬁrst phase
without withholding clinically desirable treatment escalation.
Eligible participants were randomly assigned at a ratio of
1:1 between monotherapy and combination therapy, but in
practice, randomization was 1:1:2 to treatment with 50 mg
losartan, or 12.5 mg HCTZ, as ﬁrst monotherapy, versus
50 mg losartan plus 12.5 mg HCTZ combination therapy. In
the monotherapy arms, there was forced dose-doubling after
4 weeks of treatment, then participants crossed over at
8 weeks to the alternative drug at the lower dose, which was
again force-titrated to twice the dose after a further 4 weeks.
In the combination arm, the successive dose permutations at
every 4 weeks after initial assignment were losartan/HCTZ
50/25, 100/12.5, and 100/25 mg. After 16 weeks (start of
phase 2), all participants received the combination of losartan
100 mg plus HCTZ 12.5 mg. At week 24, all participants were
force-titrated to losartan 100 mg plus HCTZ 25 mg. At week
32 (start of phase 3), amlodipine was added if systolic BP was
>140 mm Hg or diastolic BP was >90 mm Hg. There were 2
subsequent opportunities for addition or titration of amlodip-
ine, to 10 mg, with doxazosin 4 to 8 mg as a permitted
alternative or addition, as required. The study ended at
52 weeks.
Losartan and HCTZ tablets were reencapsulated in iden-
tical gelatin capsules backﬁlled with microcrystalline cellulose
and magnesium stearate, which was also used for the
matching placebo capsules. All patients received 2 capsules
throughout phase 1, in double-dummy fashion, to maintain
masking in the combination and monotherapy groups. Emer-
gency code breaks via the central Interactive Voice Response
System were available if deemed absolutely necessary. In
phases 2 and 3, losartan and HCTZ were provided in a single
tablet, the identity of which was known to investigators and
patients; however, masking of the initial assignment was
maintained until database lock.
Adherence to study medication was assessed by return
tablet count.
Home BP was measured using the Microlife WatchBP
Home monitor on the last 4 days before each clinic visit. This
was used instead of ambulatory BP monitoring to improve
patient acceptability and to minimize dropouts.
Readings were performed in triplicate, morning and
evening, after 10 minutes of seated rest. Clinic BP measure-
ments were recorded in triplicate after 10 minutes of seated
Figure 1. Schematic of the study showing drug administration in each of the 3 phases. HCTZ indicates
hydrochlorothiazide; HSBP, home systolic blood pressure.
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rest taken at each study visit using the participant’s own
Microlife monitor. Plasma renin mass was measured at
baseline, using the Diasorin Liaison automated chemilumi-
nescent immunoassay for direct renin.14 A full biochemical
series was taken at regular intervals for safety.
A cardiac magnetic resonance imaging substudy was
undertaken at 3 of the participating centers where magnetic
resonance imaging capacity for research studies existed
(Cambridge, Leicester, and Dundee) to measure left ventric-
ular (LV) mass at baseline and after treatment for 12 months.
In these centers, all participants were offered the magnetic
resonance imaging substudy until at least 60 participants had
been recruited. All cardiac magnetic resonance imaging data
were collected using a common protocol15 and processed by
clinicians (S.N., G.P.M.) blinded to treatment and other
demographics at a central site at Leicester using manual
contours drawn with CMR42 software (Circle Cardiovascular
Imaging) with exclusion of the papillary muscles and trabec-
ulations and normalized for body mass.16
All adverse events considered related to treatment were
recorded on the electronic case record form and coded by
the data management center on the basis of the medical
dictionary for regulatory activities. Serious adverse events
were documented and reported to the chief investigator
and to regulatory authorities, in accordance with local and
national requirements.
The original protocol prespeciﬁed the time of the primary
end point at the end of phase 2, namely, 32 weeks after
randomization, at which time all patients were receiving the
same therapy. The statistical analysis plan, published before
data lock and unblinding, described 2 hierarchical co–primary
end points.13 The ﬁrst was the mean reduction from baseline
of HSBP over phases 1 and 2, testing for superiority between
the losartan plus HCTZ (initial combination) group and the
mean of each monotherapy arm. The second primary end
point (tested only if the ﬁrst hypothesis was positive) was
the reduction from baseline in HSBP at week 32, a point in
the study when all participants were receiving the same
treatment.
Secondary end points included the reductions in HSBP at
52 weeks and the reductions in clinic systolic BP at the same
time points as home BP recordings. To test the “AB/CD” rule
—recommending that an angiotensin-converting enzyme
inhibitor or an angiotensin receptor blocker (ARB) or beta-
blocking drug be prescribed initially to younger patients and a
calcium antagonist or diuretic be prescribed to older
patients4,17—and whether this rule could be improved by
measurement of plasma renin,18 we examined the effect of
baseline variables, particularly age and plasma renin, on
response to each monotherapy at the end of phase 1. We also
investigated the proportion of participants who achieved
target HSBP (<135 mm Hg) and the response rates, deﬁned
as the proportion of participants with systolic BP
<135 mm Hg or reduction >10 mm Hg. The proportions of
participants with adverse events and withdrawals were
compared between treatment groups.
In the crossover substudy, we identiﬁed the monotherapy
that provided the best response in phase 1 for each
participant. We prespeciﬁed analyses to examine predictors
of the better treatment, including age >55 or <55 years (this
is the cut point for choosing between A and D in some
guidelines17) and tertiles of plasma renin.
The study was approved by Cambridgeshire Research
Ethics Committee (09/H0308/132), and all participants gave
written informed consent.
Statistical Analyses
A sample size of 268 in each group had 90% power to detect a
difference in HSBP means of 4 mm Hg, assuming a common
SD of 12 mm Hg using a 2-group t test with a=0.01. We
hypothesized 4 mm Hg because this was the difference in
systolic BP between arms in the VALUE study at 3 months
that was associated with signiﬁcant excess mortality.7
All analyses followed a prespeciﬁed statistical analysis
plan.
We used the arithmetic mean of last 18 home BP
measurements before a study visit to calculate home BP. If
>18 measurements were obtained, the earliest recorded
readings were discarded. For most patients, we used all
readings on days 1 to 3 before the visit, but if any of these
were missing, readings from day 4 before the visit were
added. The minimum number of measurements required for a
valid assessment of home BP was 6, and if there were <6
readings, we declared the observation missing.
We used mixed-effect models with unstructured covari-
ances for repeated measures within a patient. These
models provide valid tests of hypotheses when observations
are missing at random. We adjusted for prespeciﬁed
baseline covariates (sex, age, height, weight, smoking
history, whether or not the participant had been treated
for hypertension before the baseline visit, and the baseline
value of the outcome being analyzed). Least squares means
estimated from these models are presented. BP control and
response rates were analyzed using logistic regression
models, which also included the baseline covariates.
Comparisons of adverse event rates between treatments
were conducted using v2 tests, and Fisher exact P values
are given.
Intention-to-treat analyses excluded only those partici-
pants with no primary outcome data at any follow-up visit.
Other participants with missing data were included, and we
assumed that data were missing at random (ie, its absence
was unrelated to the unobserved value).
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The investigators and all authors had sole discretion in
data analysis and interpretation, writing of the report, and the
decision to submit for publication.
Results
We screened 796 patients and randomized 605 participants,
301 to initial monotherapy and 304 to initial combination
therapy; the intention-to-treat analysis included 287 and 299
participants, respectively, in these 2 groups (Figure 2).
Table 1 shows the baseline characteristics of participants
in the study and indicates that the participants receiving
combination therapy were similar to those in each monother-
apy arm.
The mean adjusted change in HSBP from baseline over
weeks 0 to 32 was 19.7 mm Hg (95% conﬁdence interval
[CI], 20.7 to 18.7) in the initial combination group, and
14.8 mm Hg (95% CI, 15.8 to 13.8) across the
monotherapy group (Figure 3A and Table 2). The difference
between groups (the primary end point) was 4.9 mm Hg
(95% CI, 6.0 to 3.7) and was signiﬁcant at P<0.001 in
favor of combination therapy, permitting testing of the second
hierarchical primary end point prespeciﬁed in the protocol. At
the end of phase 2, the mean adjusted reduction in HSBP
from baseline was 22.2 mm Hg (95% CI, 23.6 to 20.8)
in the initial combination group and 23.4 mm Hg (95% CI,
24.8 to 22.0) in participants receiving initial monotherapy.
The difference between groups for this hierarchical primary
end point was +1.2 mm Hg (95% CI, +2.8 to 0.4; P=0.1).
Clinic systolic BP largely mirrored the home BP readings
(Table 2); of note was the >10-mm Hg lower clinic BP in those
on combination therapy averaged over phase 1. Table S2
shows the home and clinic BP data split by study week, and
Table S3 shows data split by morning and evening home BP
readings. The BP-lowering effects of medication were similar
or lower in the evening, suggesting that the trial medication
lowered BP throughout the day.
By the end of phase 3, ≥75% of participants in both groups
were at target (Table S4), with no difference between groups
at the end of either phase 2 or 3. In contrast, only 40% of
responses to initial monotherapy were controlled at target at
the end of phase 1 (Figure 3B), increasing to 50% of all
responses to monotherapy (ie, on either losartan or HCTZ;
Tables S5 and S6). Post hoc analysis identiﬁed only 35
participants whose initial monotherapy was their best treat-
ment (Table S7).
In the monotherapy arm crossover, losartan and HCTZ
were the more effective drugs in younger and older
participants, respectively, but the age effect was modest,
and losartan 100 mg was more effective than HCTZ 25 mg in
most participants aged >55 years (Table 3). Participants in
the top renin tertile responded by 3.7 mm Hg more to
losartan and by 4.3 mm Hg less to HCTZ than those in the
lowest tertile, an overall difference between treatments of
8 mm Hg (Table 3, P<0.001). In contrast, the response to
796 screened
605 randomized 
304 to combinaon 
therapy
151 to HCTZ then 
losartan
150 to losartan then 
HCTZ
144 with follow-up 143 with follow-up 299 with follow-up 
102 completed 110 completed 220 completed
191 excluded
7 no follow-up 
79 withdrawn33 withdrawn42 withdrawn
5 no follow-up 7 no follow-up 
Figure 2. CONSORT (Consolidated Standards of Reporting Trials) diagram showing the patients screened,
randomized, and analyzed. Note that withdrawn participants include some patients who completed the
protocol but had major protocol deviations or who had incomplete data for the primary outcome.
“Withdrawn” equals not eligible for per protocol analysis. The breakdown of withdrawals is shown in
Table S3. HCTZ indicates hydrochlorothiazide.
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combination therapy was independent of renin tertile and, on
average, 5 mm Hg greater than the response to the best
drug for each tertile (Figure 3C). There was a greater
response to all drugs, especially losartan, in women. Previous
treatment favored response to combination, whereas
monotherapy was more effective in participants who were
na€ıve to treatment.
LV mass was measured in 85 patients (41 on combi-
nation therapy and 44 on monotherapy [22 in each
monotherapy arm]). LV mass normalized for body surface
area was signiﬁcantly reduced between baseline and the
end of the study (10.4%, P<0.001) but was not different
between the combination and sequential monotherapy arms
of the study.
Adverse Effects
Adverse and serious effects were similar with combination
therapy or monotherapy overall (Table S8). There were more
reports of symptoms suggesting hypotension on combination
therapy in phase 1 (combination 25.0% versus monotherapy
13.6%, P<0.001) and on monotherapy in phase 2 (combina-
tion 11.4% versus monotherapy 18.0%, P=0.04), but these did
not result in signiﬁcantly increased withdrawals due to
adverse effects. Table S9 shows adverse events that occurred
in at least 5% of participants on any treatment or that were
signiﬁcantly different between treatments. Some participants
were withdrawn or discontinued or did not have sufﬁcient
data for full analysis (Table S10). Figure S2 shows a Kaplan–
Meier survival analysis of time to withdrawal due to adverse
event. It also shows survival to add-on therapy in phase 3 of
the study.
Discussion
We found a large average difference in HSBP in favor of initial
use of combination therapy compared with initial monotherapy
across the ﬁrst 8 months of the study (phases 1 and 2); there
was no discernible subset of patients in whom this difference
was not observed. It was largely due to the superiority of
combination therapy in the ﬁrst 16 weeks (phase 1), by
margins of almost 8 and 10 mm Hg, respectively, for home and
clinic systolic BP. Although combination therapy is expected to
show superior efﬁcacy and is recommended for stage 2
hypertension by some guidelines, this has not yet become the
norm in routine practice. Consequently, we incorporated a
number of planned measurements in the study design that we
believed, if positive, would help to change practice.
The ﬁrst of the additional measurements was the
co–primary end point of HSBP at 32 weeks, the prespeciﬁed
time point for evaluation of the never-catch-up hypothesis
that initial less intense BP control results in subsequently
poorer BP control. This hypothesis was rejected. Never
Table 1. Patient Demographics at Baseline
Combination Therapy
Monotherapy
(HCTZ First)
Monotherapy
(Losartan First)
Age (y), mean (SD) 54.3 (12.1) 53.6 (11.9) 54.5 (12.2)
Female, n (%) 109 (36.5) 51 (35.4) 45 (31.5)
Weight, mean (SD) 86.9 (17.6) 87.5 (17.2) 86.8 (16.5)
BMI, mean (SD) 29.5 (5.6) 29.8 (5.7) 29.0 (5.0)
Diabetic, n (%) 23 (7.7) 9 (6.3) 14 (9.8)
Current smoker, n (%) 23 (7.7) 18 (12.5) 15 (10.5)
Former smoker, n (%) 102 (34.1) 53 (36.8) 47 (32.9)
Never smoked, n (%) 174 (58.2) 73 (50.7) 81 (56.6)
Never previously treated for
hypertension, n (%)
135 (45.2) 64 (44.4) 70 (49.0)
Blood pressure, mm Hg
Home systolic, mean (SD) 152.1 (11.2) 151.8 (13.4) 152.2 (12.1)
Diastolic, mean (SD) 93.2 (9.9) 93.4 (103) 93.6 (8.3)
Clinic systolic, mean (SD) 158.5 (12.0) 158.0 (13.2) 156.3 (12.5)
Diastolic, mean (SD) 98.3 (10.0) 99.3 (10.5) 98.6 (10.0)
Renin, median (IQR) 12 (6–19) 13 (6–22) 12 (7–23)
BMI indicates body mass index; HCTZ, hydrochlorothiazide; IQR, interquartile range.
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catching up in the ASCOT and VALUE trials, from which the
hypothesis arose, may be more a consequence of suboptimal
treatments being combined rather than optimal treatments
being started sequentially.7,10 In contrast, our other original
comparisons provide strong support for the rationale of initial
combination. A unique feature of PATHWAY-1 is the “trial
within a trial” of a randomized monotherapy crossover trial,
the aims of which were to ensure that each participant’s best
therapy at maximal force-titrated dose was compared with
combination therapy. Several clear-cut, connected ﬁndings
emerged. First, we established that among the baseline
predictors of BP response to each drug, plasma renin provided
a measure with substantial and signiﬁcant differences in
response to losartan and HCTZ between the outer tertiles (BP
lowering by HCTZ was greatest in the low-renin tertile and by
losartan in the high-renin tertile). Second, and in marked
contrast to the monotherapy responses, with combination
therapy, BP reduction did not vary among tertiles of renin or
with other predictors. The important practical inference is that
initial combination is not only effective but uniformly effective,
reducing the heterogeneity in response—as illustrated by the
97% responder and 75% control rates (Table S3), with odds
ratios of 8 and 5 compared with monotherapy. Third, as
graphically illustrated in Figure 3C, initial combination therapy
is not only uniformly effective and superior to monotherapy
but is uniformly superior to personalized monotherapy,
whether achieved by prediction of each patient’s best drug
or by systematic crossover between the options. Even if,
within the environment of a trial—with its forced dose-drug
titrations and ﬁxed visit appointments—BP in the monother-
apy arm caught up with initial combination by 32 weeks, it is
reasonable to suggest the marked advantage for everyday
practice of a regimen that achieves target BP in the shortest
possible time and the least number of visits.
These ﬁndings make a strong case for considering initial
combination therapy to be more effective than current
practice. Moreover, they are supported by prospective,
double-blind data to combat the other main factor blocking
uptake of initial combination: concern about adverse events.
There was no difference in the overall rate between groups.
The slight excess in phase 1 of symptoms associated with
better BP reduction did not lead to an excess of withdrawals
from the initial combination group.
These aspects demarcate PATHWAY-1 from the shorter
term, largely commercial studies comparing components of
ﬁxed-dose combinations, undertaken for registration of the
combinations. Most of these studies used lower relative doses
of one or both components than we did, and none provided
participants with the opportunity to receive both components
at maximal dose and to be compared both with matched
patients starting on combination and with their own subse-
quent response to the combination. Two larger and longer
term studies are sometimes cited to support the value of
initial combination: the prospective cluster-randomized
STITCH (Simpliﬁed Treatment Intervention to Control Hyper-
tension) study and retrospective Wald meta-analysis.19,20
A
B
C
Figure 3. Home systolic BP. A, Means at each visit in each of
the monotherapy and combination therapy arms. Unadjusted
mean home systolic BP (95% conﬁdence interval) at each visit. B,
Responder rates at the end of each phase. C, Means measured on
maximum dose of combination therapy and each monotherapy by
tertiles of renin mass measured before treatment. Unadjusted
mean home systolic BP by renin tertile. BP indicates blood
pressure; HCTZ, hydrochlorothiazide.
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Neither, however, has led to a change in practice, probably
because of the limitations imposed by cluster randomization
and retrospective analysis and because neither could address
the question of adverse events. The STITCH study authors
considered that superior BP reduction by initial combination in
their study was attributable to their use of ﬁxed-dose
combinations (largely different from the individual drugs used
in their initial monotherapy arm) and, consequently, better
adherence. Our study was not intended to address this issue
but incidentally appears to refute it because average HSBP of
the 300 patients in the initial combination arm was virtually
identical at 16 and 32 weeks (130.0 and 130.2 mm Hg,
respectively) when they were receiving losartan 100 mg and
HCTZ 25 mg as separate or single tablets.
The number of participants required to answer the primary
hypothesis for PATHWAY-1 and the median age of 55 years at
recruitment gave us the opportunity to prospectively test the
age dependence of response underpinning some guidelines,
such as National Institute for Health and Care Excellence/
British Hypertension Society and the AB/CD rule.17 These
guidelines predict that drugs blocking the renin–angiotensin
system are more effective for younger patients, whereas the
reverse is true in older patients, who tend to have lower renin.
The continuous correlation between baseline renin and BP
response, also seen in our other 2 PATHWAY studies,21,22
suggests that there may be outer extremes at which renin
predicts extreme responses; indeed, this was the case for our
patients responding as well to initial HCTZ or losartan as to
their combination (Table S7). But overall, we can conclude
that combination trumps stratiﬁcation, that initial combination
trumps initialled (=personalised) monotherapy. Indeed, our
crossover study has weakened the case for considering that 1
monotherapy can be selected with conﬁdence that it will be
effective. The renin proﬁling served rather to underpin
previous extensive literature that divides the major antihy-
pertensive drugs into 2 complementary categories, targeting
either the renin-angiotensin system or sodium balance; dual
action is required in most patients precisely to prevent the
one pressor system compensating for blockade of the
other.17,23–25
A limitation of our study is that although larger and longer
than most studies comparing combination to monotherapy,
results are limited to 1 year and cannot address the impact
on morbidity and mortality. In the VALUE study, a 3.8-mm Hg
lower clinic systolic BP in the ﬁrst 3 months of the study
translated into a signiﬁcant increase in the primary end point
driven mainly by mortality and stroke and was borderline for
increased myocardial infarction. In our study, clinic systolic BP
was 10.1 mm Hg lower in the ﬁrst 2 months and 6.8 mm Hg
on average lower over the ﬁrst 4 months on combination
therapy versus sequential monotherapy, and it is likely that
such differences applied to a large population would be
clinically important, especially those with similar cardiovas-
cular risk, as participate in morbidity–mortality studies. The
BP Lowering Treatment Trialists’ Collaboration found that the
relative risk reduction of BP lowering was similar for low- and
higher risk individuals.26 It is likely that signiﬁcant propor-
tional reductions in cardiovascular events would accrue from
treating all hypertensive patients with initial combination
therapy. Some reviewers argued that more powerful ARBs
Table 3. Predictors of BP Response on Each Treatment in Phase 1
Randomized Initial Treatment
Combination (n=299) HCTZ (n=144) Losartan (n=143)
Difference (95% CI) P Value Difference (95% CI) P Value Difference (95% CI) P Value
Top vs bottom renin tertile* 1.41 (3.52 to 0.71) 0.2 4.31 (2.26–6.35) <0.001 3.71 (5.70 to 1.71) <0.001
Aged >55 vs ≤55 y* 1.45 (0.29 to 3.19) 0.1 2.94 (4.73 to 1.15) 0.001 1.89 (3.62 to 0.16) 0.03
Renin (per 10-fold increase) 1.80 (4.75 to 1.16) 0.24 4.96 (2.12–7.80) <0.001 3.70 (6.43 to 0.97) 0.008
Age (per 10 y) 0.13 (0.85 to 1.12) 0.8 0.97 (1.98 to 0.04) 0.06 0.20 (1.18 to 0.77) 0.7
Baseline HSBP 0.29 (0.22–0.36) <0.001 0.48 (0.42–0.54) <0.001 0.55 (0.48–0.61) <0.001
Never vs previously treated 1.83 (0.41 to 4.08) 0.1 3.01 (5.26 to 0.77) 0.009 2.85 (4.96 to 0.73) 0.009
Effects Not Signiﬁcantly
Different Between Treatment Arms
Male vs female 2.40 (0.54–4.26) 0.01
Weight (per 10 kg) 0.17 (0.27 to 0.60) 0.5
Current smoker vs never 1.20 (1.08 to 3.48) 0.3
Former smoker vs never 2.00 (0.50–3.51) 0.009
Estimates of baseline covariate effects from multivariate models. BP indicates blood pressure; CI, conﬁdence interval; HCTZ, hydrochlorothiazide; HSBP, home systolic blood pressure.
*Prespeciﬁed categorization of age and renin, which were used as continuous variables for covariate adjustments in all other analyses.
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have been identiﬁed since our study was initiated, citing a
meta-analysis of azilsartan,27 or that HCTZ 25 mg is a paltry
and unacceptable diuretic because in combination with this
same ARB, it reduced systolic BP by 5.6 mm Hg less than a
combination with chlortalidone, weighting a meta-analysis of
thiazide-like versus thiazide-type diuretics.28,29 There is a
paucity of outcome data for the latter at their widely used
modern doses. These are potentiated by ARBs, with which
they are frequently combined to block the compensatory
effect of renin–angiotensin stimulation.19,22 In the only
randomized morbidity–mortality study to demonstrate supe-
riority of an ARB to an active control, losartan was combined
with HCTZ 12.5 to 25 mg in most participants.30 In a
retrospective analysis of a nonrandomized, unmatched com-
parison of HCTZ and chlortalidone, the event rate was lower in
patients receiving chlortalidone (>50 mg in 48%, specialist
intervention in 84%) rather than HCTZ (>50 mg in 28%,
specialist intervention in 45%).31 Not all international guide-
lines have been convinced of the superiority of thiazide-like
over thiazide-type diuretics, and these have been compared
directly for >12 weeks in <100 patients.29,32
A strength of the PATHWAY studies is the use of home BP
monitoring as the primary outcome measure. Measured over a
number of days and averaged, this value is a better prognostic
marker of cardiovascular disease than clinic pressure and
avoids misclassiﬁcation due to the “white coat effect” seen
with clinic measures.33 Although some guidelines now recom-
mend 24 ambulatory blood pressure measurements for initial
diagnosis, this is not a practical alternative to HBPM for routine
monitoring of treatment, and within a trial environment, the use
of serial ambulatory blood pressure monitoring for primary
outcome measurements can compromise power by increasing
dropout rates. In addition to use of HBPM, we conducted a
substudy assessing LV mass. Consistent with the large
reductions in BP over phases 1 and 2 in the combination
therapy group and over phase 2 in the monotherapy group, our
substudy found >10% reduction in LV mass, which compares
favorably with the reduction seen in other studies.18 The
absence of difference in LV mass between groups conﬁrms
rejection of the never-catch-up hypothesis and the rapidity with
which cardiovascular risk (for which LV mass is the best
surrogate) can be reversed by good BP control.
The British Hypertension Society Research Network took a
lead role in the design of ACCELERATE (Aliskiren and the
Calcium Channel blocker Amlodipine combination as an initial
treatment strategy for hypertension control),9 a previous trial
addressing questions similar to those in PATHWAY-1. That
study was unable to address the question of individual
variability and recruited a high proportion of patients on
multiple previous drugs. We aimed this time at 50% of na€ıve
patients and achieved 45%, which is rare in studies of this
size; the remaining patients had received just 1 previous drug
class. Taken together, the present study and the ACCELERATE
study9 provide a reasonable basis to suggest that the beneﬁts
of combination therapy over monotherapy are generalizable.
The present study used losartan and HCTZ, whereas
ACCELERATE used aliskiren and amlodipine, and both studies
demonstrated the superiority of initial treatment with combi-
nation therapy. Many combination tablets cost no more than
the single components. Whether further reduction of BP by
combination therapy is cost-effective and advantageous in the
40% of patients at target on monotherapy is a matter of
current interest on which forthcoming guidelines are likely to
have a view.34 Initial combination may be favored by those
who consider undertreatment to be a more prevalent problem
than overtreatment.
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Table S1 
 
Inclusion and Exclusion Criteria 
 
 
Inclusions: (patients must meet all inclusion criteria to be eligible) 
 
1. Aged 18 – 79 years. 
2. BP ≥150 mmHg (systolic) OR ≥ 95 mmHg (diastolic) after placebo run-in.  Patients may be 
included if the investigator anticipates BP criteria for inclusion will be met at randomisation (i.e. if BP is 
likely to meet criteria after withdrawal of previous monotherapy during placebo run-in phase). 
3. Either never-treated hypertension or received a maximum of one antihypertensive drug class in 
the previous year.  
4. Male subjects or female subjects taking adequate contraception such as the oral contraceptive 
pill, an intra uterine device or who are surgically sterilised or postmenopausal females. 
 
 
 
Exclusions: 
 
Patients will be excluded for ANY ONE of the following reasons  
1. Clinic SBP > 200 mmHg or DBP > 120 mmHg, with PI discretion to override if home BP 
measurements are lower. 
2. Secondary or accelerated phase hypertension.  
3. eGFR < 45 mls/min.  
4. Contra-indication or previous intolerance to any trial therapy.  
5. Failure to record required home BP readings during placebo run-in.  
6. Significant co-morbidity (investigator opinion but to include alcoholism, terminal illness, documented 
non-attendance at clinics etc).  
7. Diabetes type 1.  
8. Plasma K+ outside normal range on two successive measurements during screening.  
9. Requirement for treatment with ≥2 drugs (which can be a CCB and/or {ACEi OR ARB OR direct 
renin inhibitor OR β-blocker}) in order to reduce blood pressure to ≤180/120 mmHg.  
10. Requirement for diuretic therapy (other than for hypertension).  
11. Requirement for ACE inhibitor (or ARB) therapy (other than for hypertension).  
12. Absolute contra-indications to any of the study drugs (listed on their data-sheet).  
13. Current therapy for cancer.  
14. Anticipation of change in medical status during course of trial (e.g. planned surgical intervention 
requiring >2 weeks convalescence , actual or planned pregnancy).  
15. Inability to give informed consent. 
16. Participation in a clinical study involving an investigational drug or device within 4 weeks of 
screening.  
17. Any concomitant condition that, in the opinion of the investigator, may adversely affect the safety 
and/or efficacy of the study drug or severely limit the subject’s lifespan or ability to complete the study 
(eg, alcohol or drug abuse, disabling or terminal illness, mental disorders).  
18. Treatment with any of the following prohibited medications:  
a. Oral corticosteroids within 3 months of screening. Treatment with systemic corticosteroids is also 
prohibited during study participation.  
b. Chronic stable or unstable use of non-steroidal anti-inflammatory drugs (NSAIDs) other than 
acetylsalicylic acid is prohibited. Chronic use is defined as >3 consecutive or nonconsecutive days of 
treatment per week. In addition, the intermittent use of NSAIDs is strongly discouraged throughout the 
duration of this study. If intermittent treatment is required, NSAIDs must not be used for more than a 
total of 2 days. For all subjects requiring analgesic or anti-pyretic agents, the use of paracetamol is 
recommended during study participation.  
c. The use of short-acting oral nitrates (eg, sublingual nitroglycerin) is permitted; however, subjects 
should not take short-acting oral nitrates within 4 hours of screening or any subsequent study visit.  
d. The use of long-acting oral nitrates (eg, Isordil) is permitted; however, the dose must be stable for at 
least 2 weeks prior to screening and randomisation.  
e. The use of sympathomimetic decongestants is permitted; however, not within 1 day prior to any 
clinic visit/BP assessment.  
f. The use of theophylline is permitted; however, the dose must be stable for at least 4 weeks prior to 
screening and throughout study participation.  
g. The use of phosphodiesterase (PDE) type V inhibitors is permitted; however, subjects must refrain 
from taking these medications within 1 day of screening or any subsequent study visit.  
h. The use of alpha-blockers is not permitted – with the exception of afluzosin and tamsulosin for 
prostatic symptoms. 
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Table S2 
 
  Blood pressure Change from baseline  
Home systolic Week Combination therapy Monotherapy Combination therapy Monotherapy Difference 
Phase 1 4 136.3 (135.2 to 137.4) 143.0 (141.9  to 144.1) -15.7 (-16.8 to -14.6) -9.0 (-10.1 to -7.9) -6.70 (-8.10 to -5.31) 
 8 132.7 (131.to 133.8) 139.8 (138.7 to 140.9) -19.4 (-20.5, to 18.2) -12.2 (-13.3 to -11.1) -7.14 (-8.54 to -5.73) 
 12 133.1 (132.0 to 134.3) 141.4 (140.2 to 142.5) -18.9 (-20.0 to -17.7) -10.7 (-11.8 to -9.5) -8.22 (-9.67 to -6.76) 
 16 130.2 (129.0 to 131.4) 138.7 (137.5 to 139.9) -21.9 (-23.1 to -20.7) -13.3 (-14.5 to -12.1) -8.53 (-10.1 to -7.00) 
Phase 2 24 132.5 (131.4 to 133.7) 132.0 (130.8 to 133.1) -19.5 (-20.7 to -18.4) -20.1 (-21.2 to -18.9) 0.52 (-0.93 to 1.98) 
 32 130.0 (128.8 to 131.2) 128.4 (127.2 to 129.6) -22.0 (-23.2 to -20.8) -23.6 (-24.8 to -22.4) 1.61 ( 0.07 to 3.15) 
Phase 3 38 128.5 (127.4 to 129.6) 128.2 (127.1 to 129.3) -23.5 (-24.6 to 22.4) -23.9 (-25.0 to -22.8) 0.35 (-1.03 to 1.74) 
 44 128.1 (127.0 to 129.2) 127.0 (125.8 to 128.1) -23.9 (-25.1 to -22.8) -25.1 (-26.2 to -24.0) 1.14 (-0.26 to 2.55) 
 52 128.4 (127.2 to 129.6) 127.6 (126.4 to 128.8) -23.6 (-24.8 to -22.4) -24.5 (-25.6 to -23.3) 0.85 (-0.66 to 2.36) 
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Home diastolic       
Phase 1 4 85.0 ( 84.3 to 85.7) 89.4 ( 88.7 to 90.1) -8.3 ( -9.0 to -7.6) -3.9 ( -4.6 to -3.2) -4.39 (-5.27 to -3.51) 
 8 83.1 ( 82.4 to 83.8) 87.5 ( 86.8 to 88.2) -10.2 (-11.0 to -9.5) -5.8 ( -6.6 to -5.1) -4.41 (-5.34 to -3.48) 
 12 83.0 ( 82.2 to 83.7) 88.5 ( 87.8 to 89.3) -10.4 (-11.1 to -9.6) -4.8 ( -5.5 to -4.0) -5.59 (-6.56 to -4.62) 
 16 81.2 ( 80.5 to 82.0) 86.8 ( 86.0 to 87.6) -12.1 (-12.9 to -11.3) -6.5 ( -7.3 to -5.7) -5.58 (-6.58 to -4.58) 
Phase 2 24 82.7 ( 82.0 to 83.5) 82.6 ( 81.9 to 83.4) -10.6 (-11.4 to -9.8) -10.7 (-11.5 to -10.0) 0.11 (-0.85 to 1.08) 
 32 81.5 ( 80.7 to 82.2) 80.6 ( 79.8 to 81.4) -11.9 (-12.6 to -11.1) -12.7 (-13.5 to -12.0) 0.88 (-0.12 to 1.87) 
Phase 3 38 80.2 ( 79.5 to 81.0) 80.2 ( 79.5 to 81.0) -13.1 (-13.9 to -12.4) -13.1 (-13.9 to -12.4) 0.00 (-0.96 to 0.96) 
 44 80.0 ( 79.2 to 80.8) 79.6 ( 78.8 to 80.3) -13.3 (-14.1 to -12.6) -13.8 (-14.5 to -13.0) 0.42 (-0.56 to 1.40) 
 52 80.0 ( 79.2 to 80.8) 79.5 ( 78.7 to 80.2) -13.4 (-14.2 to -12.6) -13.9 (-14.7 to -13.1) 0.52 (-0.49 to 1.52) 
Clinic systolic       
Phase 1 4 138.7 (137.3 to 140.1) 146.4 (145.0 to 147.9) -19.1 (-20.5 to -17.7) -11.4 (-12.8 to -10.0) -7.71 (-9.49 to -5.93) 
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 8 134.3 (132.8 to 135.8) 142.9 (141.4 to 144.4) -23.5 (-25.0 to 22.0) -14.9 (-16.4 to -13.4) -8.59 (-10.5 to -6.67) 
 12 133.0 (131.5 to 134.6) 145.3 (143.8 to 146.9) -24.8 (-26.4 to 23.3) -12.5 (-14.1 to -11.0) -12.3 (-14.3 to -10.3) 
 16 130.2 (128.6 to 131.8) 141.6 (140.0 to 143.2) -27.6 (-29.2 to -26.0) -16.3 (-17.8 to -14.7) -11.4 (-13.4 to -9.31) 
Phase 2 24 133.2 (131.6 to 134.8) 133.0 (131.4 to 134.5) -24.6 (-26.2 to -23.0) -24.9 (-26.5 to -23.3) 0.27 (-1.78 to 2.32) 
 32 129.5 (127.9 to 131.0) 130.2 (128.6 to 131.7) -28.4 (-29.9 to -26.8) -27.7 (-29.2 to -26.1) -0.70 (-2.74 to 1.34) 
Phase 3 38 128.8 (127.3 to 130.3) 128.5 (127.0 to 130.0) -29.1 (-30.6 to -27.5) -29.3 (-30.8 to -27.8) 0.28 (-1.66 to 2.21) 
 44 128.1 (126.7 to 129.6) 127.6 (126.1 to 129.0) -29.7 (-31.2 to -28.2) -30.2 (-31.7 to -28.8) 0.55 (-1.32 to 2.42) 
 52 128.3 (126.8 to 129.8) 128.4 (126.9 to 129.9) -29.5 (-31.0 to -28.0) -29.4 (-30.9 to -27.9) -0.11 (-2.0 to 1.82) 
Clinic diastolic       
Phase 1 4 88.0 ( 87.0 to 88.9) 93.0 ( 92.1 to 94.0) -10.7 (-11.6 to -9.7) -5.6 ( -6.6 to -4.6) -5.06 (-6.30 to -3.83) 
 8 85.3 ( 84.3 to 86.3) 91.2 ( 90.2 to 92.2) -13.3 (-14.3 to -12.3) -7.4 ( -8.4 to -6.4) -5.90 (-7.15 to -4.64) 
 12 84.7 ( 83.8 to 85.7) 91.9 ( 91.0 to 92.8) -13.9 (-14.9 to -12.9) -6.7 ( -7.7 to -5.8) -7.16 (-8.37 to -5.95) 
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 16 83.0 ( 82.0 to 84.0) 90.3 ( 89.3 to 91.3) -15.7 (-16.7 to -14.7) -8.4 ( -9.4 to -7.4) -7.32 (-8.61 to -6.02) 
Phase 2 24 85.0 ( 84.0 to 86.0) 84.8 ( 83.8 to 85.7) -13.6 (-14.6 to -12.6) -13.9 (-14.9 to -12.9) 0.24 (-1.03 to 1.51) 
 32 82.8 ( 81.8 to 83.8) 82.9 ( 81.9 to 83.9) -15.8 (-16.8 to -14.8) -15.7 (-16.7 to -14.7) -0.12 (-1.42 to 1.18) 
Phase 3 38 82.4 ( 81.4 to 83.4) 82.1 ( 81.1 to 83.1) -16.3 (-17.3 to -15.3) -16.6 (-17.6 to -15.6) 0.29 (-1.00 to 1.58) 
 44 81.7 ( 80.7 to 82.7) 80.9 ( 79.9, 81.9) -16.9 (-17.9,-15.9) -17.8 (-18.8,-16.8) 0.85 (-0.45, 2.15) 
 52 81.9 ( 80.8, 82.9) 81.4 ( 80.4 to 82.5) -16.7 (-17.8 to -15.7) -17.2 (-18.2 to -16.2) 0.46 (-0.90 to 1.81) 
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Table S3 
 
 
Home systolic 
Mean AM and PM 
Blood 
Combination therapy 
pressure 
Monotherapy 
Change from 
Combination therapy 
baseline 
Monotherapy 
 
Difference 
p-value 
Average over phases 1 and 2 132·4 (131·4 to 133·4) 137·3 (136·3 to 138·2) -19·7 (-20·7.to -18·7) -14·8 (-15·8 to -13·8) -4·88 (-6·04 to -3·73) <0·001(1) 
End of phase 2 129·8 (128·4 to 131·3) 128·6 (127·2 to 130·0) -22·2 (-23·6 to -20·8) -23·4 (-24·8 to -22·0) 1·22 (-0·38 to -2·82) 0·134(2) 
Average over phase 1 133.0 (132.0 to 134.0) 141.0 (140.0 to 142.0) -19.0 (-20.0 to -18.0) -11.1 (-12.0 to -10.1) -7.97 (-9.14 to -6.81)  
Average over study (phases 1-3) 131·1 (130·2 to 132·0) 134·0 (133·1 to 134·9) -20·9 (-21·9 to -20·0) -18·0 (-18·9 to -17·1) -2·90 (-3·99 to -1·82)  
AM       
Average over phases 1 and 2 133.1 (132.0 to 134.1) 137.7 (136.7 to 138.8) -17.9 (-19.0 to -16.8) -13.2 (-14.3 to -12.2) -4.65 (-5.89 to -3.41) <0.001 
End of phase 2 130.2 (128.6 to 131.8) 129.5 (127.9 to 131.1) -20.8 (-22.3 to -19.2) -21.5 (-23.0 to -19.9) 0.70 (-1.08 to 2.47) 0.440 
Average over phase 1 133.7 (132.6 to 134.8) 140.9 (139.9 to 142.0) -17.2 (-18.3 to -16.2) -10.0 (-11.1 to -9.0) -7.20 (-8.45 to -5.96)  
Average over study (phases 1-3) 131.8 (130.8 to 132.8) 134.8 (133.8 to 135.8) -19.2 (-20.2 to -18.2) -16.2 (-17.2 to -15.2) -3.00 (-4.19 to -1.82)  
PM       
Average over phases 1 and 2 131.9 (130.8 to 133.0) 137.4 (136.4 to 138.5) -21.3 (-22.4 to -20.2) -15.7 (-16.8 to -14.6) -5.57 (-6.84 to -4.30) <0.001 
End of phase 2 129.5 (127.9 to 131.0) 127.8 (126.3 to 129.4) -23.6 (-25.2 to -22.1) -25.3 (-26.8 to -23.8) 1.64 (-0.12 to 3.39) 0.067 
Average over phase 1 132.4 (131.3 to 133.6) 141.4 (140.3 to 142.5) -20.7 (-21.8 to -19.6) -11.7 (-12.8 to -10.6) -8.96 (-10.3 to -7.66)  
Average over study (phases 1-3) 130.6 (129.6 to 131.6) 133.9 (132.9 to 134.9) -22.5 (-23.6 to -21.5) -19.3 (-20.3 to -18.3) -3.28 (-4.46 to -2.10)  
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Table S4 
 
Combination therapy Monotherapy 
 
Patients Met target Patients Met target 
 
Controlled(*) n r r/n (%) n r r/n (%) Odds ratio (95%CI) p-value 
 
Phase 1 
 
298 
 
223 
 
74·8 
 
287 
 
114 
 
39·7 
 
4·66 ( 3·23 to 6·70) 
 
<·001 
 
Phase 2 
 
265 
 
202 
 
76·2 
 
263 
 
206 
 
78·3 
 
0·88 ( 0·58 to 1·33) 
 
0·5 
 
Phase 3 
 
241 
 
204 
 
84·6 
 
237 
 
193 
 
81·4 
 
1·22 ( 0·75 to 2·01) 
 
0·4 
 
(*)    Home SBP<135 and home DBP<85 or clinic SBP<140 and clinic DBP<90 at final visit of Phase 1 
Responders(†‡) 
        
 
Phase 1 
 
297 
 
289 
 
97·3 
 
287 
 
237 
 
82·6 
 
8·05 ( 3·69 to 17·55) 
 
<·001 
 
Phase 2 
 
264 
 
252 
 
95·5 
 
263 
 
259 
 
98·5 
 
0·33 ( 0·10 to 1·05) 
 
0·06 
 
Phase 3 
 
240 
 
237 
 
98·8 
 
237 
 
232 
 
97·9 
 
1·70 ( 0·39 to 7·33) 
 
0·5 
 
 
 
 
(†) Controlled, or fall in home SBP >10, or fall in clinic SBP>10 at any visit in Phase 1 
 
(‡) One patient with no baseline blood pressures could not be evaluated 
Odds ratios from logistic regression models adjusted for baseline covariates 
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Table S5 
Monotherapy at weeks 8 and 16 
N <=135mmHg 
Change from baseline Home SBP 
Mean 95%CI Mean 95%CI 
 week 
144 35.3% -11.6 -13.2, -9.9 140.3 138.1,142.4 HCTZ 8 
16 143 31.3% -11.2 -13.0, -9.3 140.5 138.7,142.4 
Losartan 8 143 36.4% -12.0 -13.5, -10.5 139.8 137.9,141.6 
16 144 45.2% -14.2 -16.0, -12.4 137.4 135.3,139.6 
 
Initial monotherapy patients at target (%), home SBP (mmHg), and change from baseline, at weeks 
8 and 16 during Phase 1. The monotherapies crossed over at week 8. (post hoc analysis) 
 
 
Table S6 
Best monotherapy 
N 
<=135 
mmHg 
Change from baseline 
(mmHg) Home SBP (mmHg)  
Mean 95%CI Mean 95%CI  
HCTZ 115 46.2% (36.8,55.8) -16.8 -18.9,-14.8 136.0 133.8,138.2  
Losartan 172 52.4% (44.8,60.6) -16.3 -17.6,-14.9 134.6 133.1,136.1  
All 287 50.0% (44.0,56.0) -16.5 -17.6,-15.4 135.1 133.9,136.4  
 
Initial monotherapy patients at target on their best drug, at either week 4 or week 8 (post-hoc 
analysis) 
 
 
Table S7 
 
Better at week 32 than best at week 4 or 8?  
No Yes    p-value 
 Plasma renin (mU/L)  Plasma renin (mU/L) No vs Yes 
Initial therapy N Mean SE N Mean SE  
 
104 11.41 1.09 169 11.18 1.07 
 
Combination  
HCTZ 18 6.25 1.30 114 12.84 1.09 0.0016 
Losartan 17 21.67 1.15 115 11.05 1.08 0.0039 
 
Patients in whom initial monotherapy was as effective as, or better than, subsequent 
combination treatment. These patients lay in the outer tertiles of plasma renin. (post-hoc 
analysis)  
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Table S8 
 
 
  Combination therapy 
(N=304) 
Monotherapy 
(N=301) 
p value  
 n % n %  
 Dizziness 73 24.0 62 20.6 0.3  
 Headache 51 16.8 59 19.6 0.4  
 Nasopharyngitis 48 15.8 39 13.0 0.4  
 Fatigue 45 14.8 34 11.3 0.2  
 Cough 23 7.6 24 8.0 0.9  
 Lethargy 20 6.6 23 7.6 0.6  
 Pain in extremity 21 6.9 14 4.7 0.3  
 Back pain 14 4.6 21 7.0 0.2  
 Nausea 20 6.6 14 4.7 0.4  
 Diarrhoea 20 6.6 13 4.3 0.3  
 Arthralgia 17 5.6 19 6.3 0.7  
 Paraesthesia 17 5.6 12 4.0 0.4  
 Dyspepsia 16 5.3 3 1.0 0.004  
 Dizziness postural 16 5.3 12 4.0 0.6  
 Rash 12 3.9 16 5.3 0.4  
 Musculoskeletal pain 3 1.0 14 4.7 0.007  
 Distinct patients reporting adverse events with each preferred term. Terms listed are those that 
occurred in at least 5% of patients on any treatment, or were significantly different between 
treatments (exact p-value for Chi-Square test <0.05) 
 
  
 
 
Table S9 
 
 Combination therapy Monotherapy p value 
Serious adverse events Any time 10 (3·3%) 10 (3·3%) 1·0 
 Phase 1 5 (1·6%) 5 (1·7%) 1.0 
 Phase 2 3 (1·1%) 5 (1·9%) 0·5 
 Phase 3 2 (0·8%) 0 (0·0%) 0·5 
Any adverse event Any time 280 (92·1%) 267 (88·7%) 0·2 
 Phase 1 232 (76·3%) 214 (71·1%) 0·2 
 Phase 2 159 (58·7%) 171 (64·0%) 0·2 
 Phase 3 140 (59·1%) 125 (64·0%) 0·4 
AEs suggesting hypotension Any time 101 (33·2) 93 (30·9) 0·5 
 Phase 1 76 (25·0) 41 (13·6) <0·001 
 Phase 2 31 (11·4) 48 (18·0) 0·04 
 Phase 3 23 (9·7) 33 (14·5) 0·1 
Withdrawals for adverse events Any time 40(13·4%) 26 (9·1%) 0·1 
 Phase 1 20 (6·7%) 10 (3·5%) 0·09 
 Phase 2 14 (5·2%) 12 (4·5%) 0·8 
 Phase 3 6 (2·5%) 4 (1·7%) 0·8 
p-values for Fisher’s exact tests     
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Table S10 
 
 
 
Excluded from per protocol cohort 
 Combination 
therapy 
79 
HCTZ 
first 
42 
Losartan 
first 
33 
Major protocol deviations  7 4 6 
Recording of primary outcome incomplete  16 7 7 
Withdrawn or lost to follow up  56 31 20 
Reasons for withdrawal     
Subject unwilling to continue Phase 1 6 5 0 
 Phase 2 3 5 0 
 Phase 3 0 1 1 
 Total 9 11 1 
Lost to follow up Phase 1 4 1 1 
 Phase 2 0 3 1 
 Phase 3 0 1 1 
 Total 4 5 3 
Adverse Event Phase 1 11 2 4 
 Phase 2 11 6 6 
 Phase 3 2 0 0 
 Total 24 8 10 
Serious Adverse Event Phase 1 5 1 2 
 Phase 2 2 0 0 
 Phase 3 0 0 0 
 Total 7 1 2 
Investigator terminated participation Phase 1 1 0 0 
 Phase 2 4 3 1 
 Phase 3 1 0 0 
 Total 6 3 1 
Other Reason Phase 1 3 2 1 
 Phase 2 3 1 1 
 Phase 3 0 0 1 
 Total 6 3 3 
Total Phase 1 30 11 8 
 Phase 2 23 18 9 
 Phase 3 3 2 3 
 Total 56 31 20 
15 
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 Figure S1 
 
 
 
 
Detailed schematic of the PATHWAY 1 study showing the drug dosing schema used. 
 Figure S2 
 
 
 
Kaplan-Meier plots for time to adverse event, or time to the earlier of adverse event or add on therapy 
Wilcoxon test (gives greater weight early events): p=0.104 for withdrawals only. Log-rank test (gives greater weight to later 
events): p=0.064 for withdrawals + add-on 
 
  
